- Home
- EKSO vs SKYE Comparison
EKSO vs SKYE Comparison
Compare EKSO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EKSO | SKYE |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 44.9M |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EKSO | SKYE |
|---|---|---|
| Price | $10.01 | $0.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.50 | ★ $15.00 |
| AVG Volume (30 Days) | 70.0K | ★ 285.3K |
| Earning Date | 05-04-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.60 |
| 52 Week High | $13.50 | $5.75 |
Technical Indicators
Market Signals| Indicator | EKSO | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 32.30 |
| Support Level | $9.64 | N/A |
| Resistance Level | $10.76 | $0.83 |
| Average True Range (ATR) | 0.90 | 0.05 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 0.00 | 1.06 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.